HKPD (Cellyan Biotechnology Co) Other Current Liabilities: $0.00 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKPD Cellyan Biotechnology Co Ltd HKPD
21 GF Score
Price $0.44
! 2 Warning Signs
View Full Analysis

What is Cellyan Biotechnology Co Other Current Liabilities?

Cellyan Biotechnology Co HKPD -4.33% 21 Other Current Liabilities is $0.00 Mil as of Sep. 2025. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Cellyan Biotechnology Co's other current liabilities for the quarter that ended in Sep. 2025 was $0.00 Mil.

Cellyan Biotechnology Co's quarterly other current liabilities declined from Sep. 2024 ($0.00 Mil) to Mar. 2025 ($-0.00 Mil) but then increased from Mar. 2025 ($-0.00 Mil) to Sep. 2025 ($0.00 Mil).

Cellyan Biotechnology Co's annual other current liabilities declined from Mar. 2023 ($0.00 Mil) to Mar. 2024 ($-0.00 Mil) and declined from Mar. 2024 ($-0.00 Mil) to Mar. 2025 ($-0.00 Mil).

Cellyan Biotechnology Co Other Current Liabilities Related Terms

Cellyan Biotechnology Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Cellyan Biotechnology Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellyan Biotechnology Co Other Current Liabilities Chart

Cellyan Biotechnology Co Annual Data
Trend Mar23 Mar24 Mar25
Other Current Liabilities
0.00 -0.00 -0.00

Cellyan Biotechnology Co Semi-Annual Data
Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Other Current Liabilities Get a 7-Day Free Trial 0.00 -0.00 0.00 -0.00 0.00
HKPD
21GF Score
Cellyan Biotechnology Co Ltd HKPD
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellyan Biotechnology Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
Cellyan Biotechnology Co (HKPD) has a Other Current Liabilities of $0.00 Mil as of Sep. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Cellyan Biotechnology Co.
Is Cellyan Biotechnology Co's Other Current Liabilities too high?
Cellyan Biotechnology Co's current Other Current Liabilities is $0.00 Mil. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Other Current Liabilities compare to COSM and SNYR?
Cellyan Biotechnology Co's Other Current Liabilities of $0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Distribution company?
A good Other Current Liabilities depends on the Medical Distribution industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Cellyan Biotechnology Co. Cellyan Biotechnology Co's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Other Current Liabilities is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellyan Biotechnology Co Business Description

Address 13 Ko Fai Road, Room B1, 5th Floor, Well Town Industrial Building, Yau Tong, Kowloon, Hong Kong, HKG
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score

Get the complete analysis for HKPD

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price